Compounding Pharmacy Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Compounding Pharmacy Market 

5.1. COVID-19 Landscape: Compounding Pharmacy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Compounding Pharmacy Market, By Therapeutic Area

8.1. Compounding Pharmacy Market, by Therapeutic Area, 2024-2034

8.1.1. Pain Management

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Hormone Replacement

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Dermal Disorders

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Nutritional Supplements

8.1.4.1. Market Revenue and Forecast (2021-2034)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Compounding Pharmacy Market, By Route of Administration

9.1. Compounding Pharmacy Market, by Route of Administration, 2024-2034

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Topical

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Parenteral

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Compounding Pharmacy Market, By Application

10.1. Compounding Pharmacy Market, by Application, 2024-2034

10.1.1. Pediatric

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Geriatric

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Adult

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Veterinary

10.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Compounding Pharmacy Market, By Compounding Type

11.1. Compounding Pharmacy Market, by Compounding Type, 2024-2034

11.1.1. Pharmaceutical Dosage Alteration (PDA)

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. Pharmaceutical Ingredient Alteration (PIA)

11.1.2.1. Market Revenue and Forecast (2021-2034)

11.1.3. Currently Unavailable Pharmaceutical Manufacturing (CUPM)

11.1.3.1. Market Revenue and Forecast (2021-2034)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global Compounding Pharmacy Market, By Sterility

12.1. Compounding Pharmacy Market, by Sterility, 2024-2034

12.1.1. Sterile

12.1.1.1. Market Revenue and Forecast (2021-2034)

12.1.2. Non-sterile

12.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 13. Global Compounding Pharmacy Market, By Distribution Channel

13.1. Compounding Pharmacy Market, by Distribution Channel, 2024-2034

13.1.1. Compounding Pharmacy

13.1.1.1. Market Revenue and Forecast (2021-2034)

13.1.2. Hospital Pharmacy

13.1.2.1. Market Revenue and Forecast (2021-2034)

13.1.3. Others

13.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 14. Global Compounding Pharmacy Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.1.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.1.3. Market Revenue and Forecast, by Application (2021-2034)

14.1.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.1.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.1.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.1.7.3. Market Revenue and Forecast, by Application (2021-2034)

14.1.7.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.1.8. Market Revenue and Forecast, by Sterility (2021-2034)

14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2021-2034) 

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.1.9.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.1.9.3. Market Revenue and Forecast, by Application (2021-2034)

14.1.9.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.1.10. Market Revenue and Forecast, by Sterility (2021-2034)

14.1.11. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.2.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2.3. Market Revenue and Forecast, by Application (2021-2034)

14.2.4. Market Revenue and Forecast, by Compounding Type (2021-2034) 

14.2.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.2.8.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2.8.3. Market Revenue and Forecast, by Application (2021-2034)

14.2.9. Market Revenue and Forecast, by Compounding Type (2021-2034) 

14.2.10. Market Revenue and Forecast, by Sterility (2021-2034)

14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2021-2034) 

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.2.11.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2.11.3. Market Revenue and Forecast, by Application (2021-2034)

14.2.12. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.2.13. Market Revenue and Forecast, by Sterility (2021-2034)

14.2.14. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.2.15.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2.15.3. Market Revenue and Forecast, by Application (2021-2034)

14.2.15.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.2.16. Market Revenue and Forecast, by Sterility (2021-2034)

14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.2.17.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2.17.3. Market Revenue and Forecast, by Application (2021-2034)

14.2.17.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.2.18. Market Revenue and Forecast, by Sterility (2021-2034)

14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.3.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3.3. Market Revenue and Forecast, by Application (2021-2034)

14.3.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.3.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.3.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3.7.3. Market Revenue and Forecast, by Application (2021-2034)

14.3.7.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.3.8. Market Revenue and Forecast, by Sterility (2021-2034)

14.3.9. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.3.10.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3.10.3. Market Revenue and Forecast, by Application (2021-2034)

14.3.10.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.3.11. Market Revenue and Forecast, by Sterility (2021-2034)

14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.3.12.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3.12.3. Market Revenue and Forecast, by Application (2021-2034)

14.3.12.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.3.12.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.3.13.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3.13.3. Market Revenue and Forecast, by Application (2021-2034)

14.3.13.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.3.13.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4.3. Market Revenue and Forecast, by Application (2021-2034)

14.4.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.4.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.4.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4.7.3. Market Revenue and Forecast, by Application (2021-2034)

14.4.7.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.4.8. Market Revenue and Forecast, by Sterility (2021-2034)

14.4.9. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.4.10.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4.10.3. Market Revenue and Forecast, by Application (2021-2034)

14.4.10.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.4.11. Market Revenue and Forecast, by Sterility (2021-2034)

14.4.12. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.4.13.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4.13.3. Market Revenue and Forecast, by Application (2021-2034)

14.4.13.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.4.13.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.4.14.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4.14.3. Market Revenue and Forecast, by Application (2021-2034)

14.4.14.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.4.14.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.5.3. Market Revenue and Forecast, by Application (2021-2034)

14.5.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.5.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.5.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.5.7.3. Market Revenue and Forecast, by Application (2021-2034)

14.5.7.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.5.8. Market Revenue and Forecast, by Sterility (2021-2034)

14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Therapeutic Area (2021-2034)

14.5.9.2. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.5.9.3. Market Revenue and Forecast, by Application (2021-2034)

14.5.9.4. Market Revenue and Forecast, by Compounding Type (2021-2034)

14.5.9.5. Market Revenue and Forecast, by Sterility (2021-2034)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

Chapter 15. Company Profiles

15.1. Fresenius Kabi

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Fagron NV

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. B. Braun Medical Inc.

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Rx3 Compounding Pharmacy

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Clinigen Group PLC

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Dougherty's Pharmacy, Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Lorraine's Pharmacy

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Wedgewood Pharmacy

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Institutional Pharmacy Solutions

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Mcguff compounding pharmacy services

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms